In a study on pancreatic cancer, the upregulation of PGM3 correlated significantly with gemcitabine resistance, while inhibiting PGM3 significantly suppressed the malignant phenotype of tumor cells and enhance the drug sensitivity of gemcitabine by modulating the EGFR-Akt pathway (26). This evidence concerns the gene PGM3 and familial pancreatic carcinoma.